EPO Patent: Novel Double-Stranded RNA Sequence and Use

ChangeBridge: EPO Bulletin - Biotech (C12N)

Published March 18th, 2026

Detected March 24th, 2026

Summary

The European Patent Office has published a patent application (EP2026028973A1) for a novel double-stranded RNA sequence based on L-PGDS RNA and its use. The publication date is March 18, 2026, and it covers various designated states within Europe. The inventors have not yet been designated.

View original document View source feed page

What changed

The European Patent Office (EPO) has published patent application EP2026028973A1 concerning a novel double-stranded RNA sequence derived from L-PGDS RNA and its therapeutic applications, particularly in treating diseases like cancer. The publication date is March 18, 2026, and it is designated for numerous European states.

This patent filing represents a new intellectual property claim in the biotechnology sector. While the inventors are yet to be formally designated, the application details specific IPC classifications related to RNA sequences, pharmaceutical compositions, and their use in treating cancer. Companies operating in the biotech and pharmaceutical space should be aware of this new patent filing as it may impact their research and development activities or existing intellectual property portfolios.

Source document (simplified)

← EPO Patent Bulletin

NOVEL DOUBLE-STRANDED RNA BASED ON L-PGDS RNA SEQUENCE, AND USE THEREOF

Publication EP2026028973A1 Kind: A1 Mar 18, 2026

Inventors

The designation of the inventor has not yet been filed

IPC Classifications

C12N 15/113 20100101AFI20260207BHEP A61K 31/713 20060101ALI20260207BHEP A61K 31/7105 20060101ALI20260207BHEP A61K 47/64 20170101ALI20260207BHEP A61P 35/00 20060101ALI20260207BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →